Enzastaurin and pemetrexed exert synergistic antitumor activity in thyroid cancer cell lines in vitro

International Journal of Clinical Pharmacology and Therapeutics

Volumn 43, Issue 12, 2005, Pages 603-604

  Oberschmidt, O ^a   Eismann, U ^a   Schulz, L ^a   Struck, S ^a   Blatter, J ^b   Lahn, M M ^b   Ma, D ^b   Hanauske, Axel R ^a  

^a DEPARTMENT OF CARDIOLOGY   (Germany)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Enzastaurin; Pemetrexed; Synergistic activity; Thyroid cancer

Indexed keywords

ANTINEOPLASTIC AGENT; ENZASTAURIN; PEMETREXED; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CLONING; CELL SURVIVAL; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; THYROID CANCER;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENZYME INHIBITORS; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; INDOLES; PROTEIN KINASE C; THYROID NEOPLASMS;

EID: 29444437443     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Chou T-C, Talalay P 1984 Quantitative analysis of dose-effect relationships. The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55
2. Hanauske A-R, von Hoff DD 1993 In vitro and in vivo predictive tests. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR (eds): Cancer Medicine. 3rd edition. Lea & Febiger, Philadelphia, pp 666-671
3. Hanauske A-R, Hilsenbeck SG, von Hoff DD 2004 Human tumor screening. In: Teicher BA, Andrews PA (eds): Cancer drug discovery and development: anticancer drug development guide: preclinical screenings, clinical trials, and approval. 2nd edition. Humana Press Inc, Totowa, NJ, USA, pp 63-76
4. Keyes KA, Mann L, Sherman M, Galbreath E, Schirtzinger L, Ballard D, Chen YF, Iversen P, Teicher BA 2004 LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol 53: 133-140
5. Zhao R, Goldman ID 2004 Alimta: a new generation antifolate. The Oncologist 9: 242-244